Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Total Liabilities (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Total Liabilities for 11 consecutive years, with $170.7 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 46.49% to $170.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $170.7 million through Dec 2025, down 46.49% year-over-year, with the annual reading at $170.7 million for FY2025, 46.49% down from the prior year.
  • Total Liabilities for Q4 2025 was $170.7 million at Intellia Therapeutics, down from $176.9 million in the prior quarter.
  • The five-year high for Total Liabilities was $319.1 million in Q4 2024, with the low at $170.7 million in Q4 2025.
  • Average Total Liabilities over 5 years is $223.3 million, with a median of $222.0 million recorded in 2024.
  • The sharpest move saw Total Liabilities skyrocketed 155.28% in 2021, then crashed 46.49% in 2025.
  • Over 5 years, Total Liabilities stood at $254.2 million in 2021, then grew by 11.92% to $284.5 million in 2022, then fell by 11.85% to $250.8 million in 2023, then increased by 27.21% to $319.1 million in 2024, then plummeted by 46.49% to $170.7 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $170.7 million, $176.9 million, and $183.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.